Fig. 6
From: LncRNA CTD-2555A7.2 promotes bone formation with LncRNA-specific cascade amplification strategy
Combination of CTD-2555A7.2 binding sequence and bioengineered recombinant miR-381-3p inhibitor enhanced in situ bone formation of hMSCs. A Representative HE staining images of nude mice calvarial defection region implanted with CTD-2555A7.2 binding sequence and recombinant miR-381-3p inhibitor transfected hMSCs. Scale bar: 600 µm.B,C Expression of OCN in calvarial defection region of nude mice implanted with CTD-2555A7.2 binding sequence and recombinant miR-381-3p inhibitor transfected hMSCs, as detected by immunohistochemical staining (left). Quantification of relative integrated optical density (IOD) values of OCN immunostaining using Image-Pro Plus 6.0 software (right, mean ± SD, n = 3). Scale bar: 75μm.D Representative images showing nude mice calvarial defection region implanted with CTD-2555A7.2 binding sequence and recombinant miR-381-3p inhibitor transfected hMSCs, as detected by micro-CT. Scale bar: 1mm.E Representative images showing mineral apposition rate of nude mice calvarial defection region implanted with CTD-2555A7.2 binding sequence and recombinant miR-381-3p inhibitor transfected hMSCs. Scale bar: 10μm.F-H Calvarial bone mineral density (BMD), bone volume to tissue volume (BV/TV) and bone mineral content (BMC) of nude mice calvarial defection region implanted with CTD-2555A7.2 binding sequence and recombinant miR-381-3p inhibitor transfected hMSCs (mean ± SD, n = 3).I,J Calvarial mineral apposition rate (MAR) and bone formation rate (BFR/BS) of nude mice calvarial defection region implanted with CTD-2555A7.2 binding sequence and recombinant miR-381-3p inhibitor transfected hMSCs (mean ± SD, n = 3).**P < 0.01, ***P < 0.001
